Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSBR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSBRChampions Oncology$6.00-2.1%$6.06$5.50▼$8.74$83.34M0.397,797 shs1,409 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSBRChampions Oncology+0.49%+6.06%-1.92%+1.49%-20.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSBRChampions Oncology$6.00-2.1%$6.06$5.50▼$8.74$83.34M0.397,797 shs1,409 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSBRChampions Oncology+0.49%+6.06%-1.92%+1.49%-20.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSBRChampions Oncology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CSBR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/15/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/27/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSBRChampions Oncology$56.94M1.46$0.45 per share13.30$0.27 per share22.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSBRChampions Oncology$4.70M-$0.16N/AN/AN/A-3.94%-57.31%-7.51%7/27/2026 (Estimated)Latest CSBR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/27/2026Q4 2026CSBRChampions Oncology-$0.05N/AN/AN/A$12.89 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSBRChampions OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSBRChampions OncologyN/A0.980.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSBRChampions Oncology41.30%Insider OwnershipCompanyInsider OwnershipCSBRChampions Oncology46.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSBRChampions Oncology14313.89 million7.36 millionOptionableCSBR HeadlinesRecent News About These CompaniesCSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?July 23 at 2:21 PM | zacks.com2 Microcaps With Gross Margin CatalystsJuly 23 at 2:01 AM | zacks.comZacks Initiates Coverage of Champions Oncology With Neutral RecommendationJuly 22 at 11:16 AM | zacks.comChampions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026July 20 at 4:30 PM | accessnewswire.comAChampions Oncology (CSBR) Expected to Release Earnings on ThursdayJuly 9, 2026 | marketbeat.comChampions Oncology, Inc.: Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026April 9, 2026 | finanznachrichten.deChampions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026April 9, 2026 | accessnewswire.comAChampions Oncology, Inc.: Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology StrategyMarch 31, 2026 | finanznachrichten.deChampions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology StrategyMarch 30, 2026 | accessnewswire.comAChampions Oncology, Inc. (NASDAQ:CSBR) Q3 2026 Earnings Call TranscriptMarch 14, 2026 | insidermonkey.comChampions Oncology, Inc. (CSBR) Q3 2026 Earnings Call TranscriptMarch 12, 2026 | seekingalpha.comChampions Oncology Reports Revenue of $16.6 MillionMarch 12, 2026 | accessnewswire.comAChampions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026March 5, 2026 | accessnewswire.comAIs Champions Oncology, Inc.'s (NASDAQ:CSBR) Latest Stock Performance A Reflection Of Its Financial Health?January 17, 2026 | uk.finance.yahoo.comChampions Oncology (CSBR) Earnings Call TranscriptJanuary 7, 2026 | fool.comChampions Oncology (CSBR) Earnings TranscriptJanuary 7, 2026 | finance.yahoo.comWhy Champions Oncology, Inc.’s (CSBR) Stock Is Down 5.41%December 16, 2025 | aaii.comAChampions Oncology signals expanding radiolabeling and data platform as margin improves to 52%December 16, 2025 | msn.comChampions Oncology, Inc. (NASDAQ:CSBR) Q2 2026 Earnings Call TranscriptDecember 16, 2025 | insidermonkey.comChampions Oncology, Inc. (CSBR) Q2 2026 Earnings Call TranscriptDecember 15, 2025 | seekingalpha.comChampions Oncology Reports Record Quarterly Service Revenue of $14.9 MillionDecember 15, 2025 | accessnewswire.comAMedia Sentiment Over TimeCSBR Company DescriptionsChampions Oncology NASDAQ:CSBR$6.00 -0.13 (-2.12%) Closing price 04:00 PM EasternExtended Trading$6.06 +0.06 (+1.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Alphabet Crushed Earnings, But One Number Spooked the Market Premium Retail’s Stress Test Is Separating Winners From Losers GE Vernova Just Sent a Mixed AI Signal to Investors Otis Took Another Guidance Cut—But the Story Isn't Over Philip Morris Trimmed Guidance, But Its Growth Story Looks Unshaken The 2026 Blueprint: 6 Stocks for a Brand New Portfolio Cementing the Sky: Why NVIDIA’s Bet on Nebius Matters Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
